Johnson & Johnson’s (NYSE:JNJ) DePuy Synthes division confirmed today that it’s cutting around 2% of its 23,000-member workforce as the company weathers shifts in the healthcare market.

DePuy Synthes representatives declined to provide concrete numbers or a time line for the layoffs, but said that the company had created 80 new positions that it hopes some of its redundant employees may consider.

The orthopedics maker hopes the shifts will help it adjust to the "fundamentally changing" healthcare market and global economy, according to a statement.

"DePuy Synthes companies is transforming our operating model to enhance our ability to offer broader portfolio solutions to hospitals, provide superior product innovation and expert service to surgeons, reinforce our organizational capabilities and align our cost structure to our evolving environment," company spokeswoman Lorie Gawreluk told MassDevice.com today.

The updated structure won’t affect most employees and those that are affected will get severance benefits and career counseling, Gawreluk added.

The Wall Street Journal reported yesterday that DePuy Synthes was planning on slashing about 400 jobs, citing an internal video message featuring global orthopedics group chair Michael Orsinger who explained that the cuts were necessary to allow DePuy Synthes to bear "seismic shifts" in the healthcare market, according to the report.